There are established guidelines for monitoring AML patients with NPM1 mutations under intensive induction chemotherapy regimens, whereas there are no current guidelines for MRD testing for patients receiving non-intensive venetoclax (VEN)-based regimens. This evidence concerns the gene NPM1 and acute myeloid leukemia.